Cisplatin and DNA Damage in Ovarian Cancer
Author Information
Author(s): G. Balconi, Y. Pang, M. Broggini, F. Morali, M. Marzola, E. Erba, M. Ponti, L. Spinelli, C. Mangioni, L. Redaelli, F. Bertolero, M. D'Incalci
Primary Institution: Istituto di Ricerche Farmacologiche 'Mario Negri'
Hypothesis
Can the kinetics of DNA interstrand cross-links induced by Cisplatin provide insight into its selectivity against ovarian cancer?
Conclusion
The study found that DNA interstrand cross-links induced by Cisplatin persist for a long time in human ovarian cancer cells, which may explain the drug's selectivity for this malignancy.
Supporting Evidence
- The study observed a large heterogeneity in DNA interstrand cross-links among different patients.
- DNA interstrand cross-links persisted for prolonged time intervals after drug exposure.
- The inefficient repair of DNA damage may contribute to the drug's effectiveness against ovarian cancer.
Takeaway
Cisplatin can cause damage to the DNA in ovarian cancer cells, and this damage can last a long time, which might help explain why the drug works well for this type of cancer.
Methodology
The study used alkaline elution to quantify DNA interstrand cross-links in primary cultures of human ovarian tumors.
Potential Biases
The study may have selection bias as it used primary cultures which might not represent the entire tumor population.
Limitations
The study could not correlate the permanence of DNA-ISC to clinical response due to patients receiving multiple drugs.
Participant Demographics
The study involved 58 human ovarian tumors from 47 patients, with various types of ovarian cancer represented.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website